Adage Capital Partners’s Novo Nordisk NVO Stock Holding History

Adage Capital Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.1M	Buy	+877,635	New	+$37.7M	0.06%	323
2026 Q1	–	Sell	-475,000	Closed	-$24.2M	–	1039
2025 Q4	$24.2M	Buy	+475,000	New	+$24.3M	0.04%	426
2024 Q4	–	Sell	-794,125	Closed	-$94.6M	–	938
2024 Q3	$94.6M	Buy	794,125 +34,750	+5%	+$4.63M	0.17%	113
2024 Q2	$108M	Sell	759,375 -58,451	-7%	-$7.75M	0.2%	100
2024 Q1	$105M	Buy	817,826 +3,434	+0.4%	+$409K	0.2%	105
2023 Q4	$84.2M	Sell	814,392 -544,212	-40%	-$53.8M	0.17%	135
2023 Q3	$124M	Buy	1,358,604 +205,368	+18%	+$18.1M	0.28%	76
2023 Q2	$93.3M	Buy	1,153,236 +637,618	+124%	+$52.1M	0.2%	124
2023 Q1	$41M	Sell	515,618 -192,754	-27%	-$13.7M	0.09%	256
2022 Q4	$47.9M	Sell	708,372 -68,168	-9%	-$4M	0.11%	217
2022 Q3	$38.7M	Sell	776,540 -221,070	-22%	-$11.8M	0.1%	225
2022 Q2	$55.6M	Sell	997,610 -120,390	-11%	-$6.68M	0.13%	169
2022 Q1	$62.1M	Buy	1,118,000 +68,000	+6%	+$3.49M	0.12%	177
2021 Q4	$58.8M	Buy	+1,050,000	New	+$56.9M	0.11%	193
2020 Q4	–	Sell	-200,000	Closed	-$6.94M	–	866
2020 Q3	$6.94M	Sell	200,000 -200,000	-50%	-$6.67M	0.02%	579
2020 Q2	$13.1M	Sell	400,000 -400,000	-50%	-$12.8M	0.03%	485
2020 Q1	$24.1M	Sell	800,000 -800,000	-50%	-$23.8M	0.07%	285
2019 Q4	$46.3M	Sell	1,600,000 -600,000	-27%	-$16.6M	0.11%	221
2019 Q3	$56.9M	Sell	2,200,000 -1,000,000	-31%	-$25.3M	0.14%	179
2019 Q2	$81.7M	Buy	3,200,000 +1,820,000	+132%	+$45M	0.2%	128
2019 Q1	$36.1M	Sell	1,380,000 -350,000	-20%	-$8.6M	0.09%	260
2018 Q4	$39.9M	Buy	1,730,000 +730,000	+73%	+$16.2M	0.11%	210
2018 Q3	$23.6M	Buy	1,000,000 +400,000	+67%	+$9.76M	0.05%	365
2018 Q2	$13.8M	Sell	600,000 -400,000	-40%	-$9.51M	0.03%	495
2018 Q1	$24.6M	Sell	1,000,000 -400,000	-29%	-$10.5M	0.06%	351
2017 Q4	$37.6M	Sell	1,400,000 -200,000	-13%	-$5.09M	0.09%	275
2017 Q3	$38.5M	Buy	1,600,000 +200,000	+14%	+$4.52M	0.09%	264
2017 Q2	$30M	Buy	1,400,000 +1,200,000	+600%	+$24.2M	0.07%	329
2017 Q1	$3.43M	Buy	+200,000	New	+$3.48M	0.01%	640

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Adage Capital Partners's NVO Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Novo Nordisk (NVO) in Q2 2026: 877,635 shares worth $42.1M. The stake represents 0.06% of the portfolio and ranks #323 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in NVO as recently as Q4 2025.

Adage Capital Partners first reported a position in NVO in Q1 2017 and has held it in 29 quarters since. The position peaked at $124M in Q3 2023. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Adage Capital Partners held 877,635 shares of Novo Nordisk worth $42.1M as of Q2 2026.
Novo Nordisk was a new Adage Capital Partners position in Q2 2026.
Novo Nordisk made up 0.06% of Adage Capital Partners's portfolio in Q2 2026, its #323 holding.
Adage Capital Partners first reported a position in Novo Nordisk in Q1 2017 and has held it in 29 quarters since.
Adage Capital Partners's Novo Nordisk position peaked at $124M in Q3 2023.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.